Lenalidomide in DLBCL: Are We Past the Cell of Origin?

Abstract: Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are […]

Recently Approved Drugs Herald a New Era in Therapy for Diffuse Large B-Cell Lymphoma

H&O  What are the standard treatments for diffuse large B-cell lymphoma (DLBCL)? GN  For nearly 20 years, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has […]

How Disease Stage Impacts the Rate of Second Primary Malignancies in Patients With Diffuse Large B-Cell Lymphoma 

  H&O  How common are second primary malignancies among patients with diffuse large B-cell lymphoma (DLBCL)? MK  Nearly 60% of patients with DLBCL can be cured […]